Free Trial
NASDAQ:RNAC

Cartesian Therapeutics 8/7/2025 Earnings Report

Cartesian Therapeutics logo
$10.13 -0.15 (-1.46%)
As of 10:13 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cartesian Therapeutics EPS Results

Actual EPS
$0.50
Consensus EPS
-$0.76
Beat/Miss
Beat by +$1.26
One Year Ago EPS
N/A

Cartesian Therapeutics Revenue Results

Actual Revenue
$0.30 million
Expected Revenue
$0.77 million
Beat/Miss
Missed by -$473.00 thousand
YoY Revenue Growth
N/A

Cartesian Therapeutics Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Cartesian Therapeutics' next earnings date is estimated for Thursday, November 6, 2025, based on past reporting schedules.

Cartesian Therapeutics Earnings Headlines

Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.tc pixel
Cartesian (RNAC) Q2 Revenue Drops 99%
See More Cartesian Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cartesian Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cartesian Therapeutics and other key companies, straight to your email.

About Cartesian Therapeutics

Cartesian Therapeutics (NASDAQ:RNAC), a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

View Cartesian Therapeutics Profile

More Earnings Resources from MarketBeat